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Broad audience statement: One of the mechanisms that regulate the activity of HIPK2 is the cis auto-phosphorylation of a specific tyrosine, Y361, on the activation loop. Here, we show that phosphorylation at Y361 affects the oligomerization state, the stability, and the activity of the kinase domain of HIPK2 and induces structural rearrangements at the activation loop that are transmitted to the catalytic pocket.
Notes: For the sake of clarity, the current NCBI RefSeq for mouse HIPK2 (NP_034563.2) is adopted in this article for HIPK2 amino acid numbering. In brackets the amino acid number used in the relative references is also reported, when the previous HIPK2 NP_001129537.1 was adopted.
Introduction
The homeodomain interacting protein kinase 2 (HIPK2) is a multidomain, tyrosine(Y)-regulated serine/threonine (S/T) kinase mainly found in the nucleus. It belongs to the HIPK family, classified as a subfamily of the CMGC kinases.
1,2 By controlling gene expression or protein stability through phosphorylation of specific transcription factors or regulators, HIPK2 contributes to a vast array of biological processes that range from embryonic differentiation and development to cell response to DNA-damaging agents. [3] [4] [5] Dysfunctions of HIPK2 result in the development of diseases and abnormalities linked to increased cell proliferation, as in cancer or fibrosis. [6] [7] [8] The pleiotropic function of HIPK2 requires a tight control of its activity, achieved through the complex architecture of its functional domains and a "code" of posttranslational modifications that include ubiquitylation, sumoylation, acetylation, and phosphorylation. [9] [10] [11] Among this code, particular attention has been devoted to understand the regulatory effects of phosphorylation in the activation loop, located in the kinase core and conserved among members of the HIPK family. 9, 10, [12] [13] [14] Single or multiple phosphorylation events at the activation loop occurring via transor cis-auto-phosphorylation induce conformational changes and regulate the activity of many kinases. 15, 16 More specifically, in the dual-specificity members of the CMGC group of kinases, a cis-autophosphorylation on specific Y at the activation loop occurs on translational intermediates that form during ribosomal biosynthesis and turns kinase specificity toward S/T residues on substrates. [17] [18] [19] [20] The dualspecificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is the prototype of these dual-specificity Y phosphorylation-regulated kinases [20] [21] [22] has been recently shown to be activated through a similar mechanism. Actually, HIPK2 undergoes cisauto-phosphorylation at Y361 (Y354) in the activation loop on a translational intermediate that shows different and transient properties with respect to the mature kinase, i.e., recognition and phosphorylation of a specific Y rather than canonical S/T substrates. 9, 10 Similarly to the homologous DYRK1A, this event of phosphorylation in HIPK2 does not determine the inactive-to-active transition, but the switch of the mature kinase specificity toward S/T residues of target proteins and HIPK2 itself. Notably, HIPK2 autophosphorylates on S/T residues both inside and outside its activation loop and this activity is also maintained by the isolated kinase domain.
9,10
The relevance of Y361-cis-auto-phosphorylation has been confirmed by the fact that its absence promotes strong Y-off-target cis-auto-phosphorylation that coupled to a different distribution of the surface charge results in altered activity toward HIPK2 partners. Moreover, pharmacological inhibition of Y361 phosphorylation or the usage of Y361F mutant have been shown to promote a strong delocalization of HIPK2 into the cytoplasm, leading to accumulation into aggresomes. 9, 10 Of relevance, this behavior has been extended to each member of the HIPK family 23 while a comparable cytoplasmic accumulation has been described for HIPK2 in pathological conditions, such as in some human cancers. 10, 24 While a detailed description of the cellular effects of the absence of Y361 phosphorylation has been provided and conformational changes in the regulatory tracts of the kinase domain linked to Y361 phosphorylation have been hypothesized to control HIPK2 dual activity, 9, 10 an in vitro characterization is still lacking.
Here, we perform an in vitro evaluation of the stability, oligomerization, and activity of the wild type kinase domain (KDom) of HIPK2 (HIPK2 WT ) in comparison with two phospho-defective mutants, HIPK2 Y361F and HIPK2
K228A
. The Y361F mutant mimics HIPK2 in its Y361-unphosphorylated, not mature intermediate, i.e., an aberrant/not-fully-active HIPK2, while the HIPK2 K228A mutant is mainly inactive and unphosphorylated, given the substitution of the catalytic lysine residue. 25, 26 The auto-phosphorylation pattern of these kinase domains produced in Escherichia coli, as well as of the relative full-length proteins, has been previously mapped by mass spectrometry. 9, 10 As reported, only HIPK2 WT is phosphorylated at Y361 (Y354) while Y361F mutation abolishes the possibility for that position to be phosphorylated, and other, though aberrant, Y sites become phosphorylated. Lastly, K228A mutation inactivates the enzyme leading to the absence of phosphorylation. Our in vitro characterization of these HIPK2 KDoms-wild type and phospho-defective mutants-confirms the crosstalk between the catalytic site and the activation loop of HIPK2, highlights the existence of different conformations possibly linked to Y361 phosphorylation, and offers a possible explanation for the aberrant functions and the aggresome formation by the Y361 nonphosphorylated HIPK2 observed in mammalian cells.
Results and Discussion

Y361-phosphorylation affects HIPK2 oligomerization
Recombinant HIPK2 KDoms (HIPK2 WT , HIPK2
Y361F
, and HIPK2 K228A ) were purified by GST-affinity chromatography and, after proteolytic removal of the tag, analyzed by SDS-PAGE to evaluate protein purity (Supporting Information Fig. S1 ). The phosphorylation status was assessed by Western blotting (WB) with anti-phosphoSer/Thr and anti-phosphoTyr antibodies, before and after Lambda phosphatase (kPPase) treatment [ Fig. 1 , and HIPK2
K228A
. Samples not treated and treated with k-PPase were analyzed by immunoassay using both anti-pSer/Thr and anti-pTyr antibodies (upper panels). Ponceau staining is also shown as loading control (lower panels). The band shift to a faster mobility of dephosphorylated samples is indicative of the removal of the surface phosphates. (B) Chromatographic profiles. SEC of murine HIPK2
WT (WT), HIPK2 K228A (K228A), HIPK2 Y361F (Y361F). Elution volume is reported at the top of the corresponding peak, straight lines were added to highlight the most abundant eluted species. The minor peaks present in all chromatograms at longer retention times are consistent with the presence of a minute amount of contaminants as shown in Figure S1 that reports an SDS-PAGE of the more than 90% pure HIPK2 KDom samples. WT are linked to phosphorylation-dependent variations of the interaction with the column matrix.
In addition, the minor shoulder at 16.4 mL suggests that a small population of dimers appears in the HIPK2 WT after its dephosphorylation, though to a lesser amount than observed for HIPK2 K228A , suggesting that phosphorylation at Y361, still present after
To evaluate the contribution of Y361 phosphorylation on these results, SEC analyzes were performed on the HIPK2 Y361F KDom before and after k-PPase treatment. Consistent with our previous massspectrometry data, 10 WB analyzes showed that HIP- Table S1 ). In addition, we reliably observed a peak in the void volume of the column ($ 8.4 mL) and a few peaks at volumes ascribable to different oligomeric species [ Fig , we found that they are endowed with low temperature stability, as they disappear upon incubation at 310 K also in the control experiments without k-PPase [Supporting Information Fig. S2(B) ]. This result precludes the assessment of the effect of dephosphorylation in the higher oligomeric formation. However, their prevalence in the HIPK2 , compatible with what expected for a globular protein of about 400 folded residues. 29 This value was then used as fixed parameter to determine the T m of unfolding for the three HIPK2 KDom variants studied. 29 The denaturation curves obtained for HIPK2 WT and mutant KDoms closely approach a two-state transition (Fig. 2) . Though several conditions were explored, thermal-induced denaturation of HIPK2 KDom always resulted in irreversible formation of protein aggregates at high temperature (> 350 K). However, measuring the unfolding parameters for HIPK2 WT at different rates of heating yielded similar readouts, suggesting that the kinetics of aggregation does not affect the results. 30 Thus, we compared the T m of the three KDoms. As shown in Figure 2 , HIPK2
WT shows a T m equal to 328.2 6 0.1 K, HIPK2 K228A a T m equal to 325.2 6 0.1 K, while the HIPK2 Y361F a T m equal to 317.0 6 0.4 K.
Therefore, both mutations decrease the HIPK2 KDom stability, but the semi-conservative mutation at the regulatory Y361, that also affects the overall phosphorylation pattern, introduces a more substantial destabilization of the KDom than the inactivating, nonphosphorylated K228A mutation.
ATP-competitor binding: Evidence for the cross-talk between the catalytic pocket and the activation loop
Structural plasticity of the activation loop influences the activity of protein kinases and regulates their function. 15, 16 The arrangement that activation loop adopts upon phosphorylation at specific residues allows the interface between N-and C-lobes of the kinase domain to assume its active conformation, due to a correct organization of critical residues, including the conserved catalytic lysine (e.g., K228 in HIPK2). Consequently, failure in phosphorylation at the activation loop results in inactivation/deregulation of the enzyme due to an incorrect loop conformation. 16 To highlight structural differences in the HIPK2 KDom linked to Y361-phosphorylation, we compared static fluorescence and circular dichroism spectra of HIPK2 WT , HIPK2
K228A , and HIPK2 Y361F KDoms, but negligible differences were detected with this analysis (Supporting Information Fig. S4 ). Therefore, in a further effort to probe different conformational states of the KDom associated with Y361-phosphorylation, we measured the binding of the three HIPK2 KDom variants with chemically different ATP-competitors, i.e., (Table I) .
Next, K D values were determined also for Y361F and K228A, reported in Table I . With respect to the wild type, we observed differences of K D for the binding of PurvA and Itu to HIPK2 Y361F and for Itu binding to HIPK2 K228A highlighting an effect of these mutations on the structural arrangement of the HIPK2 active site. It is worth noting that whereas mutation at K228A in the catalytic pocket affects a residue directly involved in ATP binding [ Fig. 4(A) , site A], mutation at Y361 introduces a perturbation on the activation loop [ Fig. 4(A) , site B] that is spatially far from the binding site. Indeed, using the DYRK1A KDom in complex with its inhibitor INDY as structural template, we built a model of HIPK2 that allow us to estimate the distance between the catalytic pocket and the activation loop to be above 20 Å [ Fig. 4(A) ]. 35 Despite this distance, if sites A and B are structurally coupled, rearrangements of the activation loop (site B) due to phosphorylation at Y361 should affect the binding at the catalytic pocket (site A). Thus, to assess whether the two sites are coupled, we calculated the change in free energy Table I (DDG binding ) for ATP-competitor binding after mutation at Y361 and K228 (Table II) , using the K D constants determined with the equilibrium binding experiments (Table I) . If the two sites are energetically linked, a perturbation in the binding of ATPcompetitors induced by mutation in site A (i.e., K228A in the catalytic pocket) should correlate with binding perturbations triggered by mutation in site B (i.e., Y361F at the activation loop) [ Fig. 4(A) ]. As shown in Figure 4 Fig. 5(C,F) ]. Comparison of the residual activities measured from three independent experiments shows that Stauro and Itu similarly inhibited both KDoms, and thus, were not informative for our question. In contrast, TBID, PurvA, and SB affected the activity of HIPK2 WT but not of HIPK2 Y361F though not always with statistically significant differences [ Fig. 5(C,F) ], supporting the existence of different conformations between the two KDoms. Surprisingly, TBB similarly inhibited the activity of both KDoms when MBP was the substrate [ Fig. 5(C) ], while inhibited only HIPK2 WT when GST-HIPK2 K228A was used as substrate [ Fig. 5(F) ], suggesting that ATPcompetitors might differentially affect the kinase activity also depending on the substrate. Therefore, These observations suggest that the conformation of the activation loop, that directly interacts with the kinase targets, 16 can change depending on the nature of the substrate thus affecting the structure of the HIPK2 catalytic pocket as a consequence of the crosstalk between the two sites. Structural changes of the catalytic residues might alter the interaction with the ATP-competitive compounds, thus modulating their inhibitory activity. Furthermore, in analogy with DYRKs, 20, 22 the different sensitivity of HIPK2 WT and HIPK2 Y361F to structurally diverse ATP-competitive compounds supports the existence of different conformations of the HIPK2 catalytic site. Based on the semi-conservative nature of the Y361F mutation, these different conformations can be reasonably ascribed to the phosphorylation state of Y361. Finally, it is of interest to observe that when GST-HIPK2 K228A is the substrate some compounds such as TBID, PurvA and SB, rather than inhibiting seem to work as activators of the Y361F variant [ Fig. 5(D-F) ]. Differently from the other substrates, GST-HIPK2 K228A can bind the ATP-competitors.
Therefore, we hypothesize that binding of these compounds to GST-HIPK2 K228A might induce a conformational change in the area surrounding the ATP binding site that could increase solvent exposure of some phosphorylatable residues (i.e., Tyr), making them more accessible and available for phosphorylation by HIPK2
Y361F
. In other words, the presence of the ATP competitor bound to the GST-HIPK2 K228A active site makes some residues a better substrate for HIPK2 Y361F . This phenomenon does not occur with wild type HIPK2 and it represents another evidence that HIPK2 WT and HIPK2 Y361F are different in structure.
Conclusions
HIPK2 is an interesting molecular target for selective activation or inactivation, depending on the pathology and on the cellular context. 4, 7, 36, 37 Nevertheless, the complexity of the system jeopardizes the understanding of how specific modifications contribute to its regulation. Recently, the role of residues located in the kinase domain and in the activation loop that are phosphorylated by the protein itself or by other kinases in response to specific stress signals has been investigated. [12] [13] [14] 38 Among those, the Y361 cis-auto-phosphorylation that regulates the residual activity using MBP as nonspecific substrate, gray and black represent respectively the data obtained using GST-HIPK2 K228A and p53 as specific substrates of HIPK2. ** P < 0.01; * P < 0.05; ns P > 0.05 by One-Way ANOVA (GRAPHPAD PRISM 6.0)
HIPK2 dual activity has been described as a common mechanism for all members of the HIPK family and a detailed description of the cellular effects of its failing has been provided. 9, 10, 23 In this work, we studied the effect of Y361 phosphorylation utilizing the wild type KDom of HIPK2 and its Y361F and K228A mutants. Our data indicate that phosphorylation at Y361 affects the structure of KDom in the regulatory and catalytic tracts. This is consistent with a scenario where activation loop and catalytic pocket are in communication and explore in concert different conformations, possibly also depending on the target protein. Indeed, kinase assays suggest that ATP-competitive compounds can exert inhibition in a substrate-specific manner. In addition, we report that the stability and the oligomerization state of the KDom are influenced by the extent of protein phosphorylation and by the amino acid at position 361. Indeed, mutation at Y361 decreases the HIPK2 KDom stability and increases its tendency to form high molecular weight oligomers, resulting in a less active form of the enzyme.
Taken together our data suggest that the absence of phosphorylation at Y361 changes the HIPK2 structure, perturbs its stability, decreases its activity and affects its capability to interact with partners and with itself, increasing its tendency to form aggregates. Therefore, with the caveat that our in vitro observations are limited to the isolated kinase domain, these results offer a biochemical explanation for the abnormal behavior observed in cellular systems with the Y361-unphosphorylated full-length form, such as altered activities and specificity on substrates, and accumulation in cytoplasmic aggresomes.
9,10
Materials and Methods
Protein cloning and site-directed mutagenesis: Expression and purification
The plasmid pGEX-6P-1, containing the nucleotide sequence coding for murine HIPK2 wild type (Isoform 1, Reference Sequence: NP_034563.2 (14)) kinase domain (KDom, 165-564) was utilized (HIPK2 WT ) and expressed in frame with a Glutathione S-transferase (GST) tag at its N-terminus, and a PreScission cleavage after the tag. 10 Site-directed mutagenesis was performed by using the QuickChange Lightning kit (Agilent Technologies). Y361 was mutated into phenylanaline (HIPK2 Y361F ) and K228 was mutated into alanine (HIPK2 K228A ).
Recombinant HIPK2 WT KDom and mutants were overexpressed in E. coli and purified as detailed in Supplementary Material. Quality and quantity of purified proteins were evaluated by SDS-PAGE (Supporting Information Fig. S1 ) and UV/visible spectra using the theoretical E 280 nm 5 48820 M 21 cm
21
. Plasmid containing human p53 full-length quadruple mutant M133L/V203A/N239Y/N268D (p53), N-terminus fused to a six His-tag, a lipoyl domain and TEV cleavage site, was expressed in E. coli BL21 (DE3) strain and purified as described previously, 39 without removing the tag (Mw 60 kDa). 42 See Supporting Information Figure S7 for experimental details and data analysis.
Supporting Information
Supporting Information includes a detailed description of HIPK2 WT , HIPK2
Y361F
, and HIPK2
K228A
KDom expression and purification protocols and purity assessment by SDS-PAGE. 
